Nrf2 Signaling Pathway in Chemoprotection and Doxorubicin Resistance: Potential Application in Drug Discovery
Doxorubicin (DOX) is extensively applied in cancer therapy due to its efficacy in suppressing cancer progression and inducing apoptosis. After its discovery, this chemotherapeutic agent has been frequently used for cancer therapy, leading to chemoresistance. Due to dose-dependent toxicity, high conc...
Main Authors: | Sepideh Mirzaei, Ali Zarrabi, Farid Hashemi, Amirhossein Zabolian, Hossein Saleki, Negar Azami, Soodeh Hamzehlou, Mahdi Vasheghani Farahani, Kiavash Hushmandi, Milad Ashrafizadeh, Haroon Khan, Alan Prem Kumar |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Antioxidants |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3921/10/3/349 |
Similar Items
-
Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity
by: Milad Ashrafizadeh, et al.
Published: (2020-11-01) -
Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies
by: Sepideh Mirzaei, et al.
Published: (2021-04-01) -
Resveratrol Modulates Transforming Growth Factor-Beta (TGF-β) Signaling Pathway for Disease Therapy: A New Insight into Its Pharmacological Activities
by: Milad Ashrafizadeh, et al.
Published: (2020-07-01) -
Strange Bedfellows: Nuclear Factor, Erythroid 2-Like 2 (Nrf2) and Hypoxia-Inducible Factor 1 (HIF-1) in Tumor Hypoxia
by: Rachel K. Toth, et al.
Published: (2017-04-01) -
Pectolinarigenin Induces Antioxidant Enzymes through Nrf2/ARE Pathway in HepG2 Cells
by: Mariko Shiraiwa, et al.
Published: (2022-03-01)